Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus

World Journal of Gastroenterology

Volumn 12, Issue 47, 2006, Pages 7561-7567

  Minagawa, Masami ^a   Makuuchi, Masatoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chemotherapy; Hepatic resection; Hepatocellular carcinoma; Portal vein tumor Thrombus; Radiation; Transcatheter arterial chemoembolization

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; INTERFERON; IODINATED POPPYSEED OIL; IODINE 131; METHOTREXATE; MITOXANTRONE; PLACEBO; RECOMBINANT ALPHA INTERFERON; TEGAFUR; THALIDOMIDE; URACIL;

ANTINEOPLASTIC ACTIVITY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DRUG POTENTIATION; DRUG RESPONSE; EDITORIAL; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER RESECTION; LOW DRUG DOSE; META ANALYSIS; PATIENT SELECTION; PORTAL VEIN; PROGNOSIS; PROTON THERAPY; RADIATION DOSE; SURGICAL TECHNIQUE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBECTOMY; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR THROMBUS;

EID: 33845986704     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i47.7561     Document Type: Editorial

References (66)

1. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77: 2217-22222
2. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu. K, Yamaoka Y. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802
3. Fuster J, Garcia-Valdecasas JC, Grande L, Tabet J, Bruix J, Anglada T, Taura P, Lacy AM, Gonzalez X, Vilana R, Bru C, Sole M, Visa J. Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg 1996; 223: 297-302
4. Calvet X, Bruix J, Gines P, Bru C, Sole M, Vilana R, Rodes J. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 1990; 12: 753-760
5. Portolani N, Coniglio A. Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, Giulini SM. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229-235
6. Yamaoka Y, Ikai I, Arii S, Ichida T, Okita K, Omata M. Report of 16th national survey for primary liver cancer. Kanzo 2005; 46: 234-254
7. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodes J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology, 1999; 29: 62-67
8. Villa E, Moles A, Ferretti I, Buttafoco, P, Grottola A, Del Buono M, De Santis M, Manenti F. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000; 32: 233-238
9. Yamada R, Sato M, Kawabata M, Nakatsuka, H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401
10. Okazaki M, Higashihara H, Koganemaru. HE. Transcatheter arterial embolization for inoperable hepatocellular carcinoma. Jpn J Clin Radiol 1991; 36:535-539
11. Okazaki M, Higashihara, H, Shijo H. Diagnosis and Treatment of Hepatocellular Carcinoma 24. Chemoembolization. London: Greenwich Medical Media, 1997:307-326
12. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995; 165: 315-321
13. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659
14. Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, Deugnier YM, Gosselin M. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782-1787
15. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, Lenoir C, Attali P, Etienne JP. A randomidzed trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184
16. Madden MV, Krige JE, Bailey S, Beningfield SJ, Geddes C, Werner ID, Terblanche J. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34: 1598-1600
17. Groupe d'Etude et de Traitement du Carcinonte Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256-1261
18. Bruix J, Llovet JM, Castells A, Montana,X, Bru C, Ayuso MC, Vilana R, Rodes J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27:1578-1583
19. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, Van Steenbergen W, Buffet C, Rougier P, Adler M, Pignon JP, Roche A. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29:129-134
20. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
21. Lo CM, Ngan H, Tso, WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171
22. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442
23. Friedman MA. Primary hepatoceUular cancer-present results and future prospects. Int J Radiat Oncol Biol Phys 1983; 9: 1841-1850
24. Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S319-S328
25. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479-483
26. Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 1992; 16: 112-117
27. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923-8925
28. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-1896
29. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, Ito K. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002; 80:143-148.
30. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Masuhara M, Okita K. Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Hepatol Res 2002; 23: 7-17.
31. Lai CL, Wu PC, Lok AS, Lin HJ, Ngan H, Lau JY, Chung HT, Ng MM, Yeoh EK, Arnold M. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989; 60: 928-933
32. Patt YZ, Yoffe B, Charnsangavej C, Pazdur R, Fischer H, Cleary K, Roh M, Smith R, Noonan CA, Levin B. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 1993; 72: 2574-2582
33. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998; 55: 39-47
34. Kaneko S, Urabe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002; 62 Suppl 1: 69-73
35. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-442
36. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M. Treatment of hepatocelular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93: 557-564
37. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106:1990-1997
38. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965; 93: 200-208
39. Lewin K, Millis RR. Human radiation hepatitis. A morphologic study with emphasis on the late changes. Arch Pathol 1973; 96: 21-26
40. Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, Brown MB, DuRoss DJ, Andrews JC, Ensminger WD. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992; 23: 781-788
41. Chen SC, Lian SL, Chang WY. The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33 Suppl: S124-S127
42. Tazawa J, Maeda M, Sakai Y, Yamane M, Ohbayashi H, Kakinuma S, Miyasaka Y, Nagayama K, Enomoto N, Sato C. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001; 16: 660-665
43. Yamada K, Soejima T, Sugimoto K, Mayahara H, Izaki K, Sasaki R, Maruta T, Matsumoto S, Hirota S, Sugimura K. Pilot study of local radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Jpn J Clin Oncol 2001; 31: 147-152
44. Ishikura S, Ogino T, Furuse J, Satake M, Baba S, Kawashima M, Nihei K, Ito Y, Maru Y, Ikeda H. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002; 25:189-193
45. Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, Matsumoto S, Soejima T, Sugimura. K. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003; 57: 113-119
46. Nakagawa K, Yamashita H, Shiraishi K, Nakamura N, Tago M, Igaki H, Hosoi Y, Shiina S, Omata M, Makuuchi M, Ohtomo K. Radiation therapy for portal venous invasion by hepatocellular carcinoma. World J Gastroenterol 2005; 11: 7237-7241
47. Zeng ZC, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, Sun HC, Wang BL, Zhang JY, Jiang GL, Wang YQ. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/ or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005; 61: 432-443
48. Lin CS, Jen YM, Chiu SY, Hwang JM, Chao HL, Lin HY, Shum WY. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006; 36: 212-217
49. Hsu WC, Chan SC, Ting LL, Chung NN, Wang PM, Ying KS, Shin JS, Chao CJ, Lin GD. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Jpn J Clin Oncol 2006; 36: 93-99
50. Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, Kho KC, Kim TH, Ahn YC, Huh SJ. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005; 103: 2419-2426
51. Matsuzaki Y, Osuga T, Saito Y, Chuganji Y, Tanaka N, Shoda J, Tsuji H, Tsujii H. A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 1994; 106: 1032-1041
52. Tanaka N, Matsuzaki Y, Chuganji Y, Osuga T, Kuramoto K, Tsujii H. Proton irradiation for hepatocellular carcinoma. Lancet 1992; 340: 1358
53. Hata M, Tokuuye K, Sugahara S, Kagei K, Igaki H, Hashimoto T, Ohara K, Matsuzaki Y, Tanaka N, Akine Y. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2005; 104: 794-801
54. Kumada K, Ozawa K, Okamoto R, Takayasu T, Yamaguchi M, Yamamoto Y, Higashiyama H, Morikawa S, Sasaki H, Shimahara Y. Hepatic resection for advanced hepatocellular carcinoma with removal of portal vein tumor thrombi. Surgery 1990; 108: 821-827
55. Yamaoka Y, Kumada K, Ino K, Takayasu T, Shimahara Y, Mori K, Tanaka A, Morimoto T, Taki Y, Washida M. Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein. World J Surg 1992; 16: 1172-1176; discussion 1177
56. Ikai I, Yamaoka Y, Yamamoto Y, Ozaki N, Sakai Y, Satoh S, Shinkura N, Yamamoto M. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg 1998; 227: 433-439
57. Ohkubo T, Yamamoto J, Sugawara Y, Shimada K, Yamasaki S, Makuuchi M, Kosuge T. Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. J Am Coll Surg 2000; 191: 657-660
58. Wu CC, Hsieh SR, Chen JT, Ho WL, Lin MC, Yeh DC, Liu TJ, P'eng FK. An appraisal of liver and portal vein resection for hepatocellular carcinoma with tumor thrombi extending to portal bifurcation. Arch Surg 2000; 135: 1273-1279
59. Minagawa M, Makuuchi M, Takayama T. Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001; 233: 379-384
60. Fukuda S, Okuda K, Imamura M, Imamura I, Eriguchi N, Aoyagi S. Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery 2002; 131: 300-310
61. Poon RT, Fan ST, Ng IO, Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg 2003; 237: 376-383
62. Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004; 240: 299-305
63. Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, Kianmanesh R, Ng IO, Curley SA, Yamaoka Y, Lauwers GY, Vauthey JN. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137: 403-410
64. Ikai I, Hatano E, Hasegawa S, Fujii H, Taura. K, Uyama N, Shimahara Y. Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein. J Am Coll Surg 2006; 202: 431-438
65. Le Treut YP, Hardwigsen J, Ananian P, Saisse J, Gregoire E, Richa H, Campan P. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg 2006; 10: 855-862
66. Zhou J, Tang ZY, Wu ZQ, Zhou XD, Ma ZC, Tan CJ, Shi YH, Yu Y, Qiu SJ, Fan J. Factors influencing survival in hepatocellular carcinoma patients with macroscopic portal vein tumor thrombosis after surgery, with special reference to time dependency: a single-center experience of 381 cases. Hepatogastroenterology 2006; 53: 275-280